Lessons learned from Skylab are applied to methods of dealing with space sickness among crewmembers in their first orbital flight. Early experiences on Skylab 3 led to regularly scheduled scopalamine/dexedrine tablets ingestion. Subsequent experiences on the next Skylab mission established a 75% incidence of the sickness among first-time-in-orbit crewmembers, notably in periods of inactivity rather than work periods. Intramuscular injections are recommended to treat acute space sickness. Preflight transdermal scopalamine plus three or four doses of 5 mg amphetamine are chosen preventive measures, giving 12 hours of efficacy.


    Access

    Access via TIB

    Check availability in my library


    Export, share and cite



    Title :

    Coping with space motion sickness in Spacelab missions


    Contributors:

    Publication date :

    1981-10-01


    Type of media :

    Miscellaneous


    Type of material :

    No indication


    Language :

    English






    Space Motion Sickness and Vestibular Experiments in Spacelab

    Oman, Charles M. | SAE Technical Papers | 1982



    Early Spacelab missions

    Pace, R. E., Jr. / Craft, H. G., Jr. | NTRS | 1977